BFM
CLDX icon

Boothbay Fund Management’s Celldex Therapeutics CLDX Stock Holding History

Boothbay Fund Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-90,200
Closed -$3.07M – 1559
2024
Q3 		$3.07M Buy
+90,200
New +$3.44M 0.09% 387
2022
Q3 		– Sell
-76,200
Closed -$2.05M – 2285
2022
Q2 		$2.05M Buy
76,200
+37,900
+99% +$1.1M 0.06% 541
2022
Q1 		$1.3M Sell
38,300
-22,200
-37% -$710K 0.04% 771
2021
Q4 		$2.34M Sell
60,500
-19,200
-24% -$837K 0.07% 429
2021
Q3 		$4.3M Buy
79,700
+11,800
+17% +$554K 0.16% 195
2021
Q2 		$2.27M Buy
67,900
+67,343
+12,090% +$1.85M 0.09% 329
2021
Q1 		$1.15M Buy
557
+145
+35% +$3.33K 0.06% 527
2020
Q4 		$722K Buy
+412
New +$7.42K 0.04% 615

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return